Romiplostim for severe aplastic anemia in children and young adults
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests adding romiplostim to standard care for severe aplastic anemia (a condition where the bone marrow doesn't make enough blood cells) in patients aged 2 to 21. It aims to see if this combination improves blood cell counts in those newly diagnosed or whose disease has come back or not responded to prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 21 years.
- Diagnosed with severe aplastic anemia, either new, not responding to treatment, or relapsed.
- Receiving care from a pediatric blood specialist (hematologist/oncologist).
- If female and able to have children, agree to use effective birth control during the study and for 4 months after.
- If a stem cell donor is available, willing to delay transplant for at least 12 weeks.
- Able to give informed consent (parent/guardian or patient if 18+).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a drug called romiplostim (a bone marrow stimulant) with standard immunosuppressive therapy as a first treatment for severe aplastic anemia. It aims to improve blood cell counts and reduce the need for transfusions.
This trial tests a drug called romiplostim (Nplate) for patients whose aplastic anemia—a rare blood disorder where the bone marrow stops making enough blood cells—didn't improve after cancer treatment and hasn't responded to other medications. The drug may help your bone marrow produce more blood cells.
This study tests a drug called romiplostim to see if it can help people with non-severe aplastic anemia (NSAA) who still need regular blood transfusions even after standard treatments. Romiplostim works by stimulating your body to make more blood cells, which may reduce your need for transfusions.
This trial tests whether a medication called emapalumab can help children with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. It combines emapalumab with standard immune-suppressing therapy to try to improve blood cell counts.
This trial tests a new drug called ropustine to see if it can help people with aplastic anemia that hasn't responded to other treatments. The study is at one hospital and will monitor how well your blood counts and symptoms improve.
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.